Background: In 2013, Texas House Bill 2 (HB 2)placed restrictions on the use of medication abortion, which later were nullified with the 2016 FDA-approved mifepristone label. Methods: Using data collected directly from Texas abortion facilities, we evaluated changes in the provision and use of medication abortion during three 6-month time periods corresponding to the policy changes: before HB 2, after HB 2 and after the label change. Results: Medication abortion constituted 28% of all abortions before HB 2, 10% after implementation of the restrictions and 33% after the label change. Conclusions: Use of medication abortion in Texas rebounded after the FDA label change.
